Data Catalog

EPAD

European prevention of Alzheimer’s dementia consortium

groups: IMI Projects

tags: IMI Translational Medicine

First Name
Serge
Last Name
Van der Geyten
Affiliation
Janssen Research and Development; Janssen Pharmaceutica NV
Email
svdgeyte@its.jnj.com
Business Phone Number
3214608551
Business Fax Number
-
Business Address
Turnhoutseweg 30, B-2340 Beerse, Belgium
Project Website
http://ep-ad.org/
Version
v1.0
Date of creation of the dataset
2016-12-15
Date of the last update of the dataset
2016-12-15
Funding
IMI
Reference Publications
DOI: 10.1016/S2215-0366(15)00454-X DOI: 10.1016/j.jalz.2016.06.2365 DOI: 10.1016/j.jalz.2016.07.154 DOI: 10.1186/s13195-016-0212-z
Data Standards Implemented
CDISC
Therapeutic Area Standards (Disease Area)
-
Study Protocal Description
Available at http://datacat.uni.lu/additional_files/EPAD_Study_Protocol_Description.htm
Multi-center Study
True
Description of Cohorts
-
Study Type
OBSERVATIONAL
Study Type Comment
-
Primary Purpose
To provide a well-phenotyped population (readiness population) for the EPAD PoC trial to minimize trial screening failures
Study Phase
0 (observational study)
Intervention Model
-
Study Classification
-
Indication
Alzheimer's Disease
Age Range (Low Limit) of Study
50
Age Range (Upper Limit) of Study
-
Age Unit (of the above ranges)
Year
BMI Range
-
BMI Range (lower limit)
-
BMI Range (upper limit)
-
Informed Consent
True
Planned Arm (Description of Sub-cohorts)
-
Name of Treatment
-
Standardized Name of Treatment
-
Category
-
Dose Description
-
Organism
Homo sapiens
Body System or Organ Class
brain
Total Number of (Human) Subjects
6000
Total Number of (Non-Human) Subjects
6000
Number of Subjects in Each Cohorts (if multi-cohorts)
-
Detail Subject Composition
-
Type of Samples Collected
Blood Serum Urine CSF Sputum
Number of Samples Collected
-
Samples Details
-
Secondary Analysis
Clinical imaging